2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 220-222
Coagulation and fibrinolytic proteins are defined by the clot, but their biology extends well past it. This session assembles six studies showing that what a hemostatic protein does is context-dependent. Talks span a deep mutational stability map of tissue factor validated in human population data; rescue genetics dissecting which TFPI activities are indispensable for embryonic development; conditional deletion revealing that endothelial and hepatic stellate cell ADAMTS13 are functionally non-redundant; integrin β1–dependent FVIII signaling that preserves cerebral microvascular integrity; protection from renal fibrosis in FXII and uPAR deficiency; and a murine platform that reproduces human acute obstetric coagulopathy and its response to tranexamic acid.
Technology and Procedures, Omics Technologies, Emerging Technologies, Treatment Considerations, Biological Therapies, Gene Therapy, Women’s Health, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thrombotic Disorders, Genetic Disorders, Research, Fundamental Science, Translational Research
PAPER

596 Comparing complete versus kunitz-1 TFPI deletions reveals which of its functions are critical for development

Thomas J. Girard, PhD, Irem Eldem, MD2, Lilian Antunes Heck, PhD3, Nina Lasky4, George Broze Jr, MD5, Jorge Di Paola, MD6
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Deceased 7/19/2019, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States

Background. TFPI regulates coagulation by inhibiting FXa and the FVIIa/TF complex. Humans and mice express three-Kunitz-domain TFPIα, and membrane-anchored two-Kunitz-domain TFPIβ. Some of this TFPI is proteolytically processed into the predominant circulating lipoprotein-associated two-Kunitz-domain TFPI. Unlike humans, mice also express TFPIγ, which generates a similar lipoprotein-associated two-Kunitz-domain TFPI isoform. A key difference between human and mouse TFPI is that mice have approximately 20-fold higher circulating levels of the 2-Kunitz-domain TFPI isoform than humans. The Kunitz-2 (K2) domain of TFPI interacts with and inhibits FXa, whereas, in a FXa-dependent manner, the Kunitz-1 (K1) domain inhibits the FVIIa/TF complex. TFPI Kunitz-1 (exon 4) deletion (TFPIΔK1) causes embryonic lethality establishing TFPI’s essential role in restraining the FVIIa/TF complex. However, which of the remaining specific TFPI activities (direct FXa inhibition, protein-S cofactor activity and prothrombinase inhibition) are required for development remain unresolved.

Approach.  To define the essential functions of TFPI during development, we compared TFPI-null mice, with TFPIΔK1 mice, which express TFPI isoforms deficient in FVIIa/TF inhibition while retaining (albeit decreased) the other TFPI activities.

Results. As expected, targeted deletion of the TFPI signal peptide and K1 (exons 3 and 4) eliminated all TFPI protein expression (TFPI-null) and caused embryonic lethality. Genotyped at weaning, transgenic human TFPIα and TFPIβ each rescued  both TFPIΔK1 mice and TFPI-null mice. Expression of XK1A, a selective direct inhibitor of FVIIa, fully rescued TFPIΔK1 mice but failed to rescue any TFPI-null mice.  Similarly, PAR4 deficiency, previously reported to rescue approximately 40% of TFPIΔK1 mice, rescued 31% of TFPIΔK1 mice in our study but did not rescue TFPI-null mice. Timed matings confirmed our previous findings, with 63% survival of TFPIΔK1 embryos at embryonic day (E)11.5; in contrast, no viable TFPI-null embryos were identified at E11.5 (0/94 embryos). Treatment of pregnant dams with the FXa inhibitor rivaroxaban restored survival of 38% of TFPI-null embryos at E11.5 (p=0.003). Compared with wild-type littermates, E10.5 TFPI-null embryos were smaller, pale, lacked vascular red coloration, and appeared developmentally arrested. Analysis of embryonic expression databases demonstrated conserved expression patterns of F3 (TF), FVII, FX, TFPI, and PROS/Pros (protein S) between humans and mice, including similar yolk sac-, placenta-, liver-, and overall developmental expression profiles.

Discussion. The embryonic lethality of TFPIΔK1 mice demonstrates that TFPI-mediated inhibition of FVIIa/TF is essential for development. However, because TFPI requires FXa binding to inhibit FVIIa/TF, loss of the FXa inhibitory domain eliminates both direct FXa inhibition and FXa-dependent FVIIa/TF inhibition, preventing assessment of their individual roles in development. To overcome this limitation, we generated a XK1A transgene that mimics the FXa-TFPI complex and directly inhibits FVIIa/TF, independently of FXa. The rescue of the TFPIΔK1 mice by XK1A confirms the potency of this approach. The inability of XK1A to rescue TFPI-null mice demonstrates that direct FXa inhibition by TFPI is essential for embryonic development. In XK1A-rescued TFPIΔK1 mice, this critical FXa inhibitory activity is provided by the remaining TFPIΔK1 isoforms, establishing that both FVIIa/TF and FXa inhibition contribute independently to TFPI-mediated developmental protection.

Summary. Collectively, our rescue studies demonstrate 1) complete TFPI deficiency causes a more severe phenotype than TFPI Kunitz-1 deletion;  2) TFPI’s direct FXa inhibition and FVIIa/TF inhibition are both necessary and sufficient for embryonic development; 3) either human TFPIα or TFPIβ can rescue TFPI-null mice, thus, neither TFPIα’s protein S cofactor activity, TFPIα-mediated prothrombinase inhibition, nor the glycosyl-phosphatidyl-inositol (GPI) membrane anchor to TFPIβ are required for developmental rescue. Together, these studies establish that TFPI’s critical developmental role is mediated by its core anticoagulant functions, FXa and FVIIa/TF inhibition, while excluding previously proposed nonessential isoform-specific activities. 

Thomas J. Girard, PhD: No relevant conflicts of interest to declare.